Congressional Dish: CD134: The EpiPen Hearing

CD134: The EpiPen Hearing

Sep 25, 2016

Epinephrine injectors are life saving devices for people with food allergies and one company - Mylan Inc. - produces almost all of them. In this episode, listen to the highlights from a House Oversight and Government Reform Committee grilling of Mylan CEO Heather Bresch, and judge her justification for raising the EpiPen's price over 600% since EpiPen's competition was eliminated.

Executive Producer: Anonymous

Please support Congressional Dish:

Click here to contribute with PayPal or Bitcoin; click the PayPal "Make it Monthly" checkbox to create a monthly subscription
Click here to support Congressional Dish for each episode via Patreon
Mail Contributions to: 5753 Hwy 85 North #4576 Crestview, FL 32536

Thank you for supporting truly independent media!

Sound Clip Sources

Hearing: EpiPen Price Increases (Watch on C-SPAN)

House Oversight and Government Reform Committee, September 21, 2016. Witnesses

Heather Bresch, CEO of Mylan Inc.
Doug Throckmorton, M.D., Deputy Center Director for Regulatory Programs

Clip Timestamps

(In order of appearance in episode)

51:16 - Doug Throckmorton: Available epinephrine injectors
49:55 - Rep. John Mica (FL) and Doug Throckmorton: FDA won't discuss generic applications
0:35 - Chairman Jason Chaffetz (UT) - Introduction
9:25 - Elijah Cummings (MD): Mylan's actions that Congress is investigating
12:20 - Elijah Cummings: List of EpiPen price increases
4:10 - Jason Chaffetz: Executive compensation
16:55 - Elijah Cummings: Martin Shkreli called Congress "imbeciles"
24:10 - Heather Bresch: Introduction
28:16 - Heather Bresch: Mylan's profits from each EpiPen
47:43 - Rep. Elijah Cummings (MD) & Heather Bresch: Mylan did not give Congress requested documents
55:10 - Rep. Eleanor Holmes Norton & Heather Bresch: Will Mylan reduce the price of EpiPens?
1:23:26 - Rep. Scott DesJarlais (TN) & Heather Bresch: How long were the price increases going to continue?
1:32:10 - Rep. Gerald Connolly (VA) & Heather Bresch: Mylan's EpiPen is 94% of the epinephrine injector market.
1:56:55 - Rep. Stacey Plaskett (VI) & Heather Bresch: Why are customers paying so much for EpiPens?
2:01:04 - Rep. Mark Meadows (NC) & Heather Bresch: Everyone pays a different price in this system
2:51:15 - Rep. Bonnie Watson Coleman (NJ) & Heather Bresch: Mylan moved their headquarters to the Netherlands to pay less in U.S. taxes.
2:37:15 - Rep. Peter Welch & Heather Bresch: EpiPens cost much less in the Netherlands
1:03:15 - Rep. John Duncan (TN): Drug companies have manipulated the market.
1:44:25 - Tammy Duckworth (IL) & Heather Bresch: Mylan prohibited schools from buying from competitors
36:45 - Rep. Jason Chaffetz (UT) & Heather Bresch: Heather Bresch's explanation for why her mother used her position to get schools to buy EpiPens from Mylan
1:11:40 - Rep. Tim Walberg (MI) & Heather Bresch: Mylans plan would shift costs of EpiPens to government
1:21:16 - Rep. Stephen Lynch (MA) & Heather Bresch: Veterans Administration is able to negotiate it's drug prices, which makes them lower
53:35 - Rep. John Mica (FL) & Heather Bresch: Executive compensation at Mylan
59:19 - Rep. Eleanor Holmes Norton (DC) & Heather Bresch: What does Heather Bresch do to earn $18 million per year?
2:48:55 - Rep. Bonnie Watson Coleman (NJ) & Heather Bresch: Heather Bresch often uses a company private jet
2:13:50 - Rep. Mick Mulvaney (SC) & Heather Bresch: Mylan is getting what it deserves
3:08:08 - Rep. Glenn Grothman (WI) & Heather Bresch: Does Heather Bresch feel guilty?
3:39:40 - Rep. Jason Chaffetz & Heather Bresch: The numbers don't add up.
3:43:30 - Rep. Elijah Cummings (MD) Closing statement